SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

Autor:	Seonju Yi, Young June Choe, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, Young-Joon Park
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	COVID-19 coronavirus SARS-CoV-2 vaccine breakthrough coronavirus disease Medicine Infectious and parasitic diseases RC109-216
Zdroj:	Emerging Infectious Diseases, Vol 28, Iss 3, Pp 753-756 (2022)
Druh dokumentu:	article
ISSN:	1080-6040 1080-6059
DOI:	10.3201/eid2803.212210
Popis:	We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/21cca840a8974171adcad093d76b8ab7 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF